Combination immunomodulatory therapy produces higher clinical response rates and longer survival in patients with advanced cutaneous T-cell lymphoma and poor prognostic factors than in historical controls.
Also, investigators report, recipients of combination therapy had better response rates and overall survival, despite worse prognostic factors at baseline, than patients given photopheresis monotherapy.
To determine the efficacy of multimodality biological response therapy in cutaneous T-cell lymphoma, investigators in the Department of Dermatology and the General Clinical Research Center carried out a retrospective cohort study over 14 years in their tertiary care hospital at the University of Pennsylvania, Philadelphia, Pennsylvania.
The investigators studied a consecutive sample of 47 patients with clinical and laboratory diagnoses of the condition. Two thirds (68 percent) of the patients had stage III or IV disease and almost all (89 percent) had circulating malignant T cells.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!